Skip to main content

Biontech Value Stock - Dividend - Research Selection

Biontech SE ADR

ISIN: US09075V1026, WKN: A2PSR2

Market price date: 16.07.2021
Market price: 196,00 EUR




Biontech SE ADR Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 01-04-2021
Cash flow
Net operating cash flow -13.474.000
Capital Expenditures -66.033.000
Free cash flow -79.507.000
Balance sheet
Total Equity 1.372.000.000
Liabilities & Shareholders equity 2.319.000.000
Income statement
Net income 15.200.000
Eps (diluted) 0,060
Diluted shares outstanding 246.000.000
Net sales/revenue 482.300.000

Fundamental ratios calculated on: 16-07-2021

Ratios
Key figures 16-07-2021
Cash flow
P/C -3.578,45
   
P/FC -606,44
Balance sheet
ROI0,66
ROE59,16
Income statement
P/E3.266,67
Div. Yield0,00%
P/B35,14
P/S99,97


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol22UA.F
Market Capitalization58.479.079.424,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen EUR
Stock Split
Internetbiontech.de


Description of the company

BioNTech SE, a biotechnology company, develops and markets immunotherapies against cancer and other infectious diseases. The company is involved in the development of FixVac product candidates, including BNT111, which is in the Phase I clinical trial for advanced melanoma. BNT112, which is in Phase I / II trial in prostate cancer; BNT113, which is in Phase I for the treatment of HPV + head and neck cancer; BNT114, which is in Phase I clinical trial for triple negative breast cancer; BNT115 in Phase I Ovarian Cancer Study; and BNT116, which is in a preclinical lane for non-small cell lung cancer. It is also developing neo-antigen-specific immunotherapies such as RO7198457, which is in the Phase II clinical trial for first-line melanoma as well as the Phase I clinical trial for the treatment of multiple solid tumors. Intratumoral mRNA immunotherapy with SAR441000 in Phase I clinical trial for solid tumors; and BNT141 and BNT142 for the treatment of multiple solid tumors. The company is also developing riboCytokines, which include BNT151, BNT152, and BNT152, for several solid tumors. chimeric antigen receptor T cell immunotherapies such as BNT211 for treating multiple solid tumors and BNT212 for treating pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I / II clinical trials for the treatment of multiple solid tumors. It is also developing MVT-5873, an IgG1 monoclonal antibody that is in Phase I / II clinical trials in pancreatic cancer. BNT411, product candidate for low-molecular immunomodulators for solid tumors; and immunotherapies for infectious diseases and protein replacement therapies for rare diseases. The company works with Genentech, Inc .; Sanofi S. A .; Genmab A / S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc .; Shanghai Fosun Pharmaceutical (Group) Co., Ltd .; Regeneron Pharmaceuticals, Inc .; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, biontech.de